History of at least 1 severe asthma exacerbation within the last 12 months
A long-term, randomized, double-blind, multicenter, parallel-group, phase III study evaluating the efficacy and safety of PT027 compared to PT007 administered as needed in response to symptoms in symptomatic adults and children 4 years of age or older with asthma (Mandala) / AV003
Currently receiving care from specialist physicians (eg, pulmonologists and/or allergists) at the Investigator’s or sub-investigator’s site
Uncontrolled asthma despite receiving high-dose ICS with additional controllers, or use FDA-approved monoclonal antibodies or systemic corticosteroids or other systemic immunosuppressants for the treatment of severe asthma
A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States.
Have a diagnosis of chronic atopic dermatitis for at least 1 year
Have symptoms of moderate to severe AD when you enter the study
Have not responded to topical medications or needed systemic therapy to control their AD
A phase III, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with hereditary angioedema.
Age between 2 and < 12 years old at the time of study enrollment
Have a confirmed diagnosis of Hereditary Angioedema type I or II
Have at least one HAE attack per three months
Takeda / Shire
An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age